A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia

Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / mortality
  • Male
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Survival Rate
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Piperidines
  • ibrutinib
  • Vidarabine
  • Adenine
  • fludarabine